You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 金斯瑞生物科技(1548.HK)漲6% 中和抗體測試獲FDA緊急使用授權
格隆匯 02-08 11:16
格隆匯2月8日丨金斯瑞生物科技(1548.HK)近日自低位反彈,6日累計大漲逾30%。報12.94港元,漲5.72%,總市值252.86億港元。金斯瑞生物科技公佈,直接全資附屬公司GS美國獲美國食品藥品監督管理局(FDA)生物製品評估與研究中心(CBER)授權,將cPass SARS-CoV-2中和抗體檢測試劑盒用於恢復期血漿篩查,為FDA授權的首個能在不使用活病毒的情況下專門檢測COVID-19中和抗體的測試。中和抗體可阻斷病毒感染細胞的能力,是公認的免疫生物標記。公司表示,cPass試劑盒已在歐洲取得歐洲合格認證標誌,並獲巴西ANVISA及新加坡衞生科學局批准。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account